Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

Potent LpxC Inhibitors with In Vitro Activity against Multidrug-Resistant Pseudomonas aeruginosa.

Krause KM, Haglund CM, Hebner C, Serio AW, Lee G, Nieto V, Cohen F, Kane TR, Machajewski TD, Hildebrandt D, Pillar C, Thwaites M, Hall D, Miesel L, Hackel M, Burek A, Andrews LD, Armstrong E, Swem L, Jubb A, Cirz RT.

Antimicrob Agents Chemother. 2019 Oct 22;63(11). pii: e00977-19. doi: 10.1128/AAC.00977-19. Print 2019 Nov.

PMID:
31451507
2.

Optimization and Mechanistic Characterization of Pyridopyrimidine Inhibitors of Bacterial Biotin Carboxylase.

Andrews LD, Kane TR, Dozzo P, Haglund CM, Hilderbrandt DJ, Linsell MS, Machajewski T, McEnroe G, Serio AW, Wlasichuk KB, Neau DB, Pakhomova S, Waldrop GL, Sharp M, Pogliano J, Cirz RT, Cohen F.

J Med Chem. 2019 Aug 22;62(16):7489-7505. doi: 10.1021/acs.jmedchem.9b00625. Epub 2019 Aug 9.

PMID:
31306011
3.

Optimization of LpxC Inhibitors for Antibacterial Activity and Cardiovascular Safety.

Cohen F, Aggen JB, Andrews LD, Assar Z, Boggs J, Choi T, Dozzo P, Easterday AN, Haglund CM, Hildebrandt DJ, Holt MC, Joly K, Jubb A, Kamal Z, Kane TR, Konradi AW, Krause KM, Linsell MS, Machajewski TD, Miroshnikova O, Moser HE, Nieto V, Phan T, Plato C, Serio AW, Seroogy J, Shakhmin A, Stein AJ, Sun AD, Sviridov S, Wang Z, Wlasichuk K, Yang W, Zhou X, Zhu H, Cirz RT.

ChemMedChem. 2019 Aug 20;14(16):1560-1572. doi: 10.1002/cmdc.201900287. Epub 2019 Aug 5.

PMID:
31283109
4.

Exploring the active site of the Streptococcus pneumoniae topoisomerase IV-DNA cleavage complex with novel 7,8-bridged fluoroquinolones.

Laponogov I, Pan XS, Veselkov DA, Cirz RT, Wagman A, Moser HE, Fisher LM, Sanderson MR.

Open Biol. 2016 Sep;6(9). pii: 160157.

5.

Plazomicin is effective in a non-human primate pneumonic plague model.

Mega WM, Doyle-Eisele M, Cass RT, Kostrub CF, Sherwood RL, Metz MA, Cirz RT.

Bioorg Med Chem. 2016 Dec 15;24(24):6429-6439. doi: 10.1016/j.bmc.2016.08.049. Epub 2016 Aug 27.

6.

Structural and initial biological analysis of synthetic arylomycin A2.

Roberts TC, Smith PA, Cirz RT, Romesberg FE.

J Am Chem Soc. 2007 Dec 26;129(51):15830-8. Epub 2007 Dec 1.

PMID:
18052061
7.

Controlling mutation: intervening in evolution as a therapeutic strategy.

Cirz RT, Romesberg FE.

Crit Rev Biochem Mol Biol. 2007 Sep-Oct;42(5):341-54. Review.

PMID:
17917871
8.

Complete and SOS-mediated response of Staphylococcus aureus to the antibiotic ciprofloxacin.

Cirz RT, Jones MB, Gingles NA, Minogue TD, Jarrahi B, Peterson SN, Romesberg FE.

J Bacteriol. 2007 Jan;189(2):531-9. Epub 2006 Nov 3.

9.

Defining the Pseudomonas aeruginosa SOS response and its role in the global response to the antibiotic ciprofloxacin.

Cirz RT, O'Neill BM, Hammond JA, Head SR, Romesberg FE.

J Bacteriol. 2006 Oct;188(20):7101-10.

10.

Side effects may include evolution.

Cirz RT, Gingles N, Romesberg FE.

Nat Med. 2006 Aug;12(8):890-1. No abstract available.

PMID:
16892033
11.

Induction and inhibition of ciprofloxacin resistance-conferring mutations in hypermutator bacteria.

Cirz RT, Romesberg FE.

Antimicrob Agents Chemother. 2006 Jan;50(1):220-5.

12.

Inhibition of mutation and combating the evolution of antibiotic resistance.

Cirz RT, Chin JK, Andes DR, de Crécy-Lagard V, Craig WA, Romesberg FE.

PLoS Biol. 2005 Jun;3(6):e176. Epub 2005 May 10.

Supplemental Content

Support Center